Background The use of thrombolysis in patients with acute, intermediate-risk pulmonary
embolism (PE) remains controversial. This meta-analysis compared the efficacy and safety …

The use of fibrinolytic agents in acute pulmonary embolism (PE), first described over 50
years ago, hastens the resolution of RV stain, leading to earlier hemodynamic improvement …

Determining the optimal duration of anticoagulant therapy following an acute pulmonary
embolism (PE) remains a significant challenge for clinicians. Before considering …

Background Pulmonary embolism (PE) is a critical condition requiring effective management
strategies. Several options are available, including thrombolytic therapy and anticoagulants …

Background The role of fibrinolytic therapy in patients with intermediate-risk pulmonary
embolism is controversial. Methods In a randomized, double-blind trial, we compared …

Anticoagulation (AC) is a sine qua non for the treatment of venous thromboembolism. The
addition of thrombolytics to AC is associated with more effective and efficient lysis of the …

PURPOSE: This study validated the performance of BACS, PE-SARD, Kuijer, and RIETE
scores in predicting 30-day major bleeding events in patients with pulmonary embolism (PE) …

While systemic intravenous thrombolysis decreases mortality in patients with high-risk
pulmonary embolism (PE), it clearly increases haemorrhagic risk. There are many …

Acute pulmonary embolism represents a major complication of venous thromboembolism
that is associated with high morbidity and mortality. Guidelines recommend the rapid …

Abstract Background/Introduction The current guidelines and existing bleeding risk scores
focus on assessing the risk of anticoagulant-related bleeding in patients with pulmonary …